KRYS Krystal Biotech, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1711279 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY26.0%
TTM net income YoY13.2%
TTM EPS YoY10.3%
Revenue 3-yr CAGR280.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin48.4%
Net margin47.9%
FCF margin66.0%
EBITDA margin49.7%
Returns
ROE17.5%
ROA15.9%
ROIC (approx.)23.0%
Asset turnover0.33x
Leverage & solvency
Liabilities / assets9.5%
Debt / equity0.00x
Current ratio7.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.44x
Accruals ratio-7.0%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20212022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $389.13M | $290.51M | $50.70M | $0 | $0 |
| R&D expense | $58.05M | $53.58M | $46.43M | $42.46M | $27.88M |
| SG&A expense | $146.74M | $113.63M | $98.29M | $77.73M | $40.39M |
| Operating income | $161.29M | $65.75M | -$109.62M | -$145.20M | -$68.28M |
| Interest expense | — | — | $0 | $0 | $1.49M |
| Pretax income | $189.47M | $95.36M | $12.90M | -$139.97M | -$69.57M |
| Income tax | -$15.36M | $6.20M | $1.97M | $0 | $0 |
| Net income | $204.83M | $89.16M | $10.93M | -$139.97M | -$69.57M |
| EBITDA | $167.02M | $71.72M | -$104.61M | -$142.55M | -$66.43M |
| EPS (basic) | 7.08 | 3.12 | 0.40 | -5.49 | -3.13 |
| EPS (diluted) | 6.84 | 3.00 | 0.39 | -5.49 | -3.13 |
| Weighted avg. shares (diluted) | 29.95M | 29.74M | 27.75M | 25.49M | 22.20M |
| Balance sheet | |||||
| Cash & equivalents | $496.30M | $344.87M | $358.33M | $161.90M | $341.25M |
| Short-term investments | $331.49M | $252.65M | $173.85M | $217.27M | $96.85M |
| Receivables | $127.42M | $104.75M | $42.04M | $0 | — |
| Inventory | $40.48M | $26.51M | $6.99M | $0 | — |
| Current assets | $1.02B | $742.04M | $587.91M | $383.78M | $442.27M |
| PP&E, net | $150.78M | $155.17M | $161.20M | $161.68M | $112.36M |
| Total assets | $1.33B | $1.06B | $818.36M | $558.45M | $626.29M |
| Current liabilities | $102.94M | $102.00M | $33.09M | $28.85M | $25.74M |
| Total liabilities | $114.23M | $109.46M | $39.71M | $36.22M | $32.72M |
| Shareholders' equity | $1.22B | $946.38M | $778.64M | $522.23M | $593.58M |
| Shares outstanding | 29.19M | 28.79M | 28.24M | 25.76M | 25.21M |
| Cash flow statement | |||||
| Operating cash flow | $200.87M | $123.42M | -$88.80M | -$100.57M | -$47.94M |
| Capital expenditure | $11.95M | $4.24M | $11.80M | $52.98M | $68.34M |
| Free cash flow | $188.91M | $119.18M | -$100.60M | -$153.55M | -$116.27M |
| Investing cash flow | -$58.42M | -$163.44M | $82.64M | -$114.08M | -$226.77M |
| Financing cash flow | $8.71M | $27.01M | $202.75M | $35.35M | $347.69M |
| Depreciation & amortization | $5.72M | $5.97M | $5.01M | $2.64M | $1.85M |
| Stock-based compensation | $54.51M | $49.13M | $39.93M | $33.23M | $15.32M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.